Welcome to the first of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions involving digital assets are an increasing focus for pharmaceuticals, medical device and medtech companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how digital differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
Culture clash? In this first episode we consider cultural differences between life science and technology companies and the implications those differences have for digital dealmaking. Click below to listen. You can add the podcast series to one of several apps, such as Apple Podcasts, by clicking the "+ Follow" link.
To learn more, follow this link here to download a copy of the report that accompanies the podcast series.
